Endovion - Scandion Oncology
Alternative Names: NS 3728; SCO-101Latest Information Update: 28 Jul 2022
Price :
$50 *
At a glance
- Originator NeuroSearch
- Developer Saniona; Scandion Oncology
- Class Antianaemics; Antineoplastics; Bromobenzenes; Eye disorder therapies; Fluorinated hydrocarbons; Phenylurea compounds; Small molecules; Tetrazoles
- Mechanism of Action ATP binding cassette transporter subfamily G member 2 inhibitors; Chloride channel antagonists; Cyclin-dependent kinase-activating kinase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Colorectal cancer
- Phase I/II Pancreatic cancer
- No development reported Breast cancer
- Discontinued Age-related macular degeneration; Sickle cell anaemia
Most Recent Events
- 28 Jul 2022 No recent reports of development identified for phase-I development in Breast-cancer in Denmark (PO, Capsule)
- 30 Jun 2021 Alligator Bioscience plans a clinical trial for Cancer (Combination therapy), in combination with mitazalimab and FOLFIRINOX
- 27 Oct 2020 Phase-I/II clinical trials in Pancreatic cancer (Combination therapy, Inoperable/Unresectable, Late-stage disease, Metastatic disease) in Denmark (PO) (NCT04652206)